Varying Effects of Common Tuberculosis Drugs on Enhancing Clofazimine Activity in vitro
There is recent interest in understanding how clofazimine (CFZ) might be involved in shortening the treatment of both MDR-TB and drug-susceptible TB. The present study made a number of interesting observations that may help explain the unique ability of CFZ to shorten TB therapy, by demonstrating acid pH enhancement of CFZ activity, the varying degrees of enhancement of CFZ activity against stationary phase bacilli by different TB drugs, with PZA and RIF having the highest degree of enhancement, followed by quinolones (moxifloxacin and levofloxacin), amikacin and PAS. Future studies are needed to validate our in vitro findings in animal models of TB infection.
- Downloaded 283 times
- Download rankings, all-time:
- Site-wide: 65,942 out of 109,821
- In microbiology: 5,207 out of 9,238
- Year to date:
- Site-wide: 99,447 out of 109,821
- Since beginning of last month:
- Site-wide: 77,547 out of 109,821
Downloads over time
Distribution of downloads per paper, site-wide
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!